Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine

The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanamori, Hikaru, Sawada, Yu, Sato, Sayaka, Hara, Reiko, Minokawa, Yoko, Sugino, Hitomi, Saito‐Sasaki, Natsuko, Yamamoto, Kayo, Okada, Etsuko, Nakamura, Motonobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349828/
http://dx.doi.org/10.1002/cia2.12248
Descripción
Sumario:The coronavirus disease 2019 (COVID‐19) vaccine is positively changing the health crises of this pandemic and is currently essential to overcome the COVID‐19 pandemic. The vaccine shows high efficacy against the infection and impairs the severity of symptoms. However, this vaccination is associated with concerns, such as vaccine‐associated adverse reactions, which are currently highlighted issues for clinicians. We experienced two cases of mild cutaneous adverse reaction following COVID‐19 vaccine administration, which was successfully controlled by prior administration of the antihistamine agent fexofenadine 3 days before COVID‐19 vaccination for 7 days.

Ejemplares similares